durvalumab,tremelimumab
astrazeneca
[]
neoadjuvant tremelimumab and durvalumab for resectable dmmr/msi-h gastric/gej cancer (infinity trial). path cr 60%! #gi23 
Asst Professor, GI oncologist @columbiacancer. Former med onc fellow @sloan_kettering. 🏳️‍🌈 Runner 🏃🏻, 🦮🌿 dad.